Published in Eur Urol on June 12, 2012
The Global Prevalence of Infections in Urology Study (GPIU) | NCT03665467
Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate? Urology (2013) 1.42
The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol (2015) 1.25
Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int (2014) 1.18
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol (2013) 1.03
Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates. World J Urol (2013) 0.98
An antimicrobial prophylaxis protocol using rectal swab cultures for transrectal prostate biopsy. World J Urol (2015) 0.89
Prostate biopsies should be performed according to a standard of care. Eur Urol (2012) 0.89
Nomogram for prediction of prostate cancer with serum prostate specific antigen less than 10 ng/mL. J Korean Med Sci (2014) 0.86
Bacterial prostatitis. World J Urol (2013) 0.86
Nociceptive and inflammatory mediator upregulation in a mouse model of chronic prostatitis. Pain (2015) 0.81
Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks? Radiat Oncol (2015) 0.80
Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer. Int J Clin Exp Pathol (2014) 0.79
Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative. World J Urol (2016) 0.78
Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer (2016) 0.78
A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance. World J Urol (2016) 0.78
Urinary biomarkers for prostate cancer. Curr Opin Urol (2015) 0.78
Reducing Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Systematic Review. Rev Urol (2016) 0.77
The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study. Can Urol Assoc J (2015) 0.77
Infection after transrectal ultrasound-guided prostate biopsy. Korean J Urol (2015) 0.76
Assessment of PSA-Age volume score in predicting positive prostate biopsy findings in Turkey. Int Braz J Urol (2015) 0.75
Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing. PLoS One (2015) 0.75
Clinical importance of the antibiotic regimen in transrectal ultrasound-guided biopsy: quinolone versus cephalosporin. BMC Urol (2016) 0.75
Strategies for prevention of ultrasound-guided prostate biopsy infections. Infect Drug Resist (2016) 0.75
Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA. Rev Urol (2013) 0.75
Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers. PLoS One (2016) 0.75
Prostate biopsy for the interventional radiologist. J Vasc Interv Radiol (2014) 0.75
The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections. Pathogens (2016) 0.75
Author'S reply. Cent European J Urol (2013) 0.75
Single Dose of Levofloxacin versus Three Dosages for Prophylaxis in Prostate Biopsy. Int Sch Res Notices (2014) 0.75
Outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi Infections after Prostate Biopsies, France, 2014. Emerg Infect Dis (2016) 0.75
Planning for the post-antibiotic era - why we must avoid TRUS-guided biopsy sampling. Nat Rev Urol (2016) 0.75
Prevalence of infections associated with prostate biopsy. Rev Urol (2014) 0.75
Urinary Tract Infections. Antibiotics (Basel) (2014) 0.75
Morbidity and psychological impact of prostate biopsy: the future calls for a change. Asian J Androl (2014) 0.75
Radical prostatectomy in the presence of ongoing refractory ESBL Escherichia coli bacterial prostatitis. BMJ Case Rep (2014) 0.75
[Antibiotic prophylaxis for transrectal prostate biopsy]. Urologe A (2016) 0.75
Transrectal ultrasound guided prostate biopsy in the era of increasing fluoroquinolone resistance: prophylaxis with single-dose ertapenem. World J Urol (2017) 0.75
Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol (2016) 0.75
Fiducial marker guided prostate radiotherapy: a review. Br J Radiol (2016) 0.75
Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events. Int J Clin Oncol (2015) 0.75
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis (2011) 12.29
Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis (2010) 6.70
Categorisation of complications and validation of the Clavien score for percutaneous nephrolithotomy. Eur Urol (2012) 4.11
Uncomplicated urinary tract infections. Dtsch Arztebl Int (2011) 4.01
Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS (2005) 2.92
Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol (2009) 2.80
The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol (2007) 2.77
Varicocele and male factor infertility treatment: a new meta-analysis and review of the role of varicocele repair. Eur Urol (2011) 2.41
Does imaging modality used for percutaneous renal access make a difference? A matched case analysis. J Endourol (2012) 2.38
Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors. Eur Urol (2006) 2.08
The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents (2009) 2.04
Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol (2012) 1.96
Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur Urol (2006) 1.89
Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents (2011) 1.89
EAU guidelines for the management of genitourinary tuberculosis. Eur Urol (2005) 1.87
The percutaneous nephrolithotomy global study: classification of complications. J Endourol (2011) 1.84
Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection. PLoS One (2010) 1.82
Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol (2012) 1.81
Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. BMJ (2008) 1.70
A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol (2006) 1.67
Simple urethral dilatation, endoscopic urethrotomy, and urethroplasty for urethral stricture disease in adult men. Cochrane Database Syst Rev (2012) 1.66
Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol (2004) 1.64
Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis (2007) 1.63
Outcome of dorsal buccal graft urethroplasty for recurrent bulbar urethral strictures. BJU Int (2008) 1.59
Simple urethral dilatation, endoscopic urethrotomy, and urethroplasty for urethral stricture disease in adult men. Cochrane Database Syst Rev (2010) 1.56
Host imprints on bacterial genomes--rapid, divergent evolution in individual patients. PLoS Pathog (2010) 1.54
Genome wide identification of promoter binding sites for H4K12ac in human sperm and its relevance for early embryonic development. Epigenetics (2012) 1.53
Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev (2012) 1.50
Toll-like receptor 4 expression and cytokine responses in the human urinary tract mucosa. Infect Immun (2004) 1.48
European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents (2007) 1.48
Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie's disease. Eur Urol (2007) 1.47
Surgical treatments for men with benign prostatic enlargement: cost effectiveness study. BMJ (2009) 1.44
Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: results of a prospective approach. J Urol (2004) 1.43
Congenital phimosis in patients with and without lichen sclerosus: distinct expression patterns of tissue remodeling associated genes. J Urol (2012) 1.41
Are antisperm antibodies really associated with proven chronic inflammatory and infectious diseases of the male reproductive tract? Eur Urol (2008) 1.40
Molecular basis of commensalism in the urinary tract: low virulence or virulence attenuation? Infect Immun (2007) 1.39
Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis (2010) 1.39
Uropathogenic Escherichia coli as a model of host-parasite interaction. Curr Opin Microbiol (2006) 1.32
The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int (2007) 1.30
Diagnosis and management for urosepsis. Int J Urol (2013) 1.24
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol (2008) 1.21
Expression and distribution of cholinergic receptors in the human urothelium. Life Sci (2007) 1.20
Predicting the outcome of prostatectomy using noninvasive bladder pressure and urine flow measurements. Eur Urol (2006) 1.19
Prevalence of hospital-acquired urinary tract infections in urology departments. Eur Urol (2006) 1.17
Treatment of bacterial urinary tract infections: presence and future. Eur Urol (2006) 1.17
Infections and urolithiasis: current clinical evidence in prophylaxis and antibiotic therapy. Arch Ital Urol Androl (2008) 1.12
Escherichia coli, fimbriae, bacterial persistence and host response induction in the human urinary tract. Int J Med Microbiol (2005) 1.12
Pathophysiology of erectile dysfunction. J Sex Med (2005) 1.12
ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male (2009) 1.11
Preoperative assessment of the patient and risk factors for infectious complications and tentative classification of surgical field contamination of urological procedures. World J Urol (2011) 1.10
Optimal management of urosepsis from the urological perspective. Int J Antimicrob Agents (2007) 1.10
Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int J Antimicrob Agents (2006) 1.10
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother (2005) 1.07
Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int J Antimicrob Agents (2005) 1.07
Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol (2010) 1.06
Primary seminal vesicle carcinoma detected at transurethral resection of prostate. Urology (2007) 1.06
Diagnostic value of magnetic resonance imaging in Peyronie's disease--a comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Urol (2003) 1.05
Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents (2006) 1.03
Bacterial hypermutation: clinical implications. J Med Microbiol (2011) 1.03
Do type 1 fimbriae promote inflammation in the human urinary tract? Cell Microbiol (2007) 1.02
Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. J Urol (2010) 1.02
Bacterial interference--is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? Int J Antimicrob Agents (2006) 1.01
Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers. Antimicrob Agents Chemother (2013) 1.01
Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol (2013) 1.00
Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int J Cancer (2007) 1.00
Urosepsis--from the view of the urologist. Int J Antimicrob Agents (2011) 1.00
French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med Mal Infect (2012) 0.99
MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol (2002) 0.99
Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol (2011) 0.99
Both protamine-1 to protamine-2 mRNA ratio and Bcl2 mRNA content in testicular spermatids and ejaculated spermatozoa discriminate between fertile and infertile men. Hum Reprod (2007) 0.98
Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ (2008) 0.97
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. Histochem Cell Biol (2006) 0.97
Antibiotic prophylaxis in urology departments, 2005-2010. Eur Urol (2012) 0.96
An update on uncomplicated urinary tract infections in women. Curr Opin Urol (2009) 0.96
Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int J Antimicrob Agents (2004) 0.95
Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opin Pharmacother (2007) 0.95
Bacterial control of host gene expression through RNA polymerase II. J Clin Invest (2013) 0.95